Search results
Showing 1 to 10 of 10 results for bimekizumab
Evidence-based recommendations on bimekizumab (Bimzelx) for treating axial spondyloarthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
In development [GID-TA11045] Expected publication date: TBC
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
In development [GID-TA10871] Expected publication date: 19 March 2025
Find out more about NICE's new proportionate approach to technology appraisals
Awaiting development [GID-TA11150] Expected publication date: TBC
Discontinued [GID-TA11171]
Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]
Discontinued [GID-TA11151]